Advances in understanding of innate and adaptive immune responses to viral vectors are informing the design and application of vectors for single and multiple dose regimens
This review focuses on vector re-administration to the mucosal surface of the lung. Here, immune responses are generally viewed as undesirable. This contrasts with applications, such as cancer therapies or vaccines, in which immunostimulation is a goal. Pulmonary barriers to viral pathogens broadly fall into two groups, physical and immunological. Physical barriers include mucociliary clearance and access to receptors (Figure 1 ). Immunological barriers are the innate and adaptive immune responses that have evolved to protect the host. Often, the pulmonary barriers to natural pathogens are just as effective at preventing gene transfer with therapeutic viral vectors. Innate immune responses to viruses or viral vectors are pre-existing or generated within minutes to hours after administration. In contrast, adaptive immunity requires days to weeks to develop. The innate immunity front-line in a healthy lung is patrolled by phagocytes (for example, alveolar macrophages) that quickly engulf vector particles, and thereby prevent transduction of target cells. Other phagocytic cell types, such as neutrophils, dendritic cells and natural killer T cells, are recruited in response to viral vectors or pathogens (Figure 1 ).
In brief Progress
Advances in understanding of innate and adaptive immune responses to viral vectors are informing the design and application of vectors for single and multiple dose regimens. Pre-existing immunity may prevent the success of a single administration of a viral vector. Strategies to allow adenoviral vector re-administration have been assessed. Adeno-associated virus vectors can be re-administered successfully through the use of novel serotypes, chemical formulations or immunosuppression. Re-administration studies using lentiviral vectors are beginning to inform the field of their potential for repeated delivery.
Prospects
Genome shuffling and directed evolution of the AAV capsids may help to evade immune responses. Mouse re-administration studies will be repeated in larger, more genetically diverse animal models. Novel vector formulations or transient immunosuppressive agents may facilitate vector re-administration. Incorporating microRNA targets into vectors may provide a novel strategy to prevent transgene expression in antigen-presenting cells.
Phagocytic cells and epithelia express Toll-like receptors (TLRs) and RIG-I-like (retinoid-inducible gene 1-like) receptors, which recognize nucleic acids or proteins derived from viral pathogens. 1 Examples for these include viral DNA, single-stranded RNA and double-stranded RNA. Stimulation of TLRs initiates signaling cascades consisting of at least two distinct pathways (Figure 2) . The first is a MyD88-dependent activation of transcription factor NF-kB, which induces the secretion of pro-inflammatory chemokines and cytokines. The second pathway induces type I interferons (IFN). Subsequent induction of IFN-stimulated genes leads to the activation of antiviral factors, such as RNAactivated protein kinase. The RIG-I-like (retinoid-inducible gene 1-like) receptors such as RIG-I, Mda5 and LGP2 are expressed in the cytoplasm and recognize viral RNA. 1 The cytokine responses after delivery of a single dose of adenoviral (AdV) or adeno-associated virus (AAV) vector to the lung have been well studied. Many preclinical studies and clinical trials with AdV vectors document increases in systemic chemokines and proinflammatory cytokines including RANTES, IP-10, MIP-2, IFN-g, TNF-a, IL-6 and IL-12 in humans and mice.
Cytokine responses after lentiviral vector (LV) delivery are less well studied. After a single delivery of titermatched feline immunodeficiency virus (FIV), AdV5 or vehicle to the nasal epithelia of mice, we observed a transient, early increase in IL-6 and KC (a human IL-8 ortholog). 2 These data suggest that vehicle impurities and/or simple physical irritation of the respiratory mucosa are sufficient to elicit transient cytokine release. Importantly, these cytokine responses did not preclude persistent transgene expression after LV transduction.
Pre-existing immunity may prevent the success of a single administration of viral vector
Adenovirus
Most adult humans have pre-existing immunity against many of the human AdV serotypes after exposure through natural infections. Pre-existing viral immunity is serotype-dependent and some AdV serotypes are less prevalent than others. Such immunity against a native serotype may significantly reduce the efficiency of gene transfer from a recombinant AdV of the same serotype. ). One theory implies that the number of antibodies required to neutralize the invading virus correlates to the surface area of the particle. Neutralization presumably occurs through physical interference of viral interactions with cell surface receptors. 6 
Lentivirus
In contrast to the encapsidated AdV and AAV vectors, the more genetically and structurally simple LV particle contains fewer proteins. Therefore, the diversity of antigens presented by a pseudotyped lentivirus is typically more limited. Although the consequences of repeat administration of lentivirus vectors are less well studied, some details are emerging. The responses to the replication competent viruses from which the vectors are derived have been described in some detail. For example, G-U-rich single-stranded RNA derived from HIV-1 can stimulate dendritic cells and macrophages through TLR-7 (mouse) or TLR-8 (human), and induce the secretion of IFN-a and other pro-inflammatory cytokines (reviewed in Kawai and Akira 1 ). Furthermore, murine retroviruses activate B cells through TLR-4 ( Figure 2 ), initiating TLRmediated production of pro-inflammatory cytokines and chemokines. Viruses and presumably viral vectors naturally activate TLRs and PKR, and induce early innate responses. TLR signaling leads to DC activation, which in turn initiates CD4+ and CD8+ T-cell differentiation necessary to generate adaptive cellular immune responses. In addition, one might anticipate that the vector particle itself or contaminants within the vector preparation may confer adjuvant activity. Clearly, AdV-, AAV-or LV-induced immune responses direct the magnitude of T-cell responses, and ultimately shape the levels and persistence of vector-expressed proteins.
Strategies to allow AdV vector re-administration have been assessed
The host responses to the re-administration of AdV are the most investigated; however, there is growing interest in anti-AAV and LV adaptive immune responses. Robust pulmonary immune responses to AdV have been observed in rodents and non-human primates. In human trials with AdV, neutralizing antibodies were found in bronchoalveolar and nasal lavage and serum. Re-administration of therapeutic doses of AdV to the airways in the absence of acute or chronic immunosuppression will require novel strategies.
Using alternate serotypes (serotype switching) is a strategy proposed to evade immune responses, allow repeated administration and prolong expression from AdV. Although Mastrangeli and co-workers showed in animal studies that serotype switching between AdV 4, 5 and 30 confers some ability to re-administer vector, this work has not been translated to the clinic. In addition, cytotoxic T lymphocyte (CTL) responses to conserved vector proteins remain persistent problems limiting longterm expression.
Covalent AdV capsid modification with polyethylene glycol (PEGylation) and other carriers has been shown to mask vector epitopes and achieve protective activity against neutralizing antibodies in vitro, and to a lesser degree, in vivo. The covalent linkage of PEG to free lysine residues on the vector capsid confers this effect. Croyle and colleagues reported that the transduction efficiency of PEGylated AdV was not reduced in vivo. Eto et al. 7 used a strategy that combined integrin-targeting RGD peptide and PEG to modify the AdV that enhanced gene transfer in both Coxsackie-adenovirus receptor-positive and -negative cells.
Further, the formulation of AdV with lipids and other carriers may also facilitate AdV re-administration. Formulation of AdV with dioleoylphosphatidylethanolamine, carbamoyl cholesterol or dexamethasone-spermine delivered at day 0 allowed improved expression from a re-administered AdV delivered at day 21 in contrast to no formulation. 8 This approach reduced, but did not eliminate, immune responses. The vector formulations were associated with a reduction in neutralizing antibodies, selected decreases in early cytokine responses and decreased CD4 lymphocyte infiltrates in lung tissues. A posited mechanism is that the antiinflammatory properties of the cationic lipid dexamethasone-spermine formulation improve the profile for in vivo use. Additional studies in large animal models with more diverse immune systems are needed to appreciate feasibility of translating this finding into a human clinical application.
Helper-dependent (HD) or 'gutted' adenovirus vectors were developed to eliminate the expression of viral proteins. 9 It is important to note that the HD vectors retain all the AdV capsid proteins. In some settings, the expression from HD-AdV is remarkably long-lived. 10 Koehler et al., 11 showed the dose-dependent feasibility of HD-AdV re-administration to the lungs of mice. Reporter gene (b-galactosidase) expression was reduced by B10% when a low dose (1.5 Â 10 10 particles) of HD-AdV without a transgene was followed by HD-AdV with the b-galactosidase transgene. However, when HD-AdV was delivered at a higher dose (5 Â 10 10 particles), reporter gene expression was reduced by about 80% compared with a single administration. Repeated administration of the higher vector dose was associated with increased anti-AdV-neutralizing antibodies in the BAL and serum compared with the lower dose protocol. In animal studies of systemic administration of PEGylated vectors, PEG treatment of HD-AdV reduced early innate immune Prospects of repeated pulmonary administration PL Sinn et al responses to vector administration, in part, due to reduced uptake of vector by macrophages and dendritic cells. These data indicate that, although HD adenoviruses show promise for more prolonged expression in vivo as compared with first-generation vectors, re-administration still poses significant challenges for long-term therapies for chronic disease conditions.
11
In
immunosuppression
Initial attempts at AAV re-administration to the rabbit lung resulted in transduction that was not significantly different from that from single administration; in addition, repeated administration led to the appearance of neutralizing antibodies to the viral capsid. However, one additional application succeeded in transducing murine lung after treatment with anti-CD40 ligand and soluble CTL4-Ig fusion at time of initial AAV vector exposure, due to suppression of the humoral immune response. In contrast, in non-human primates, treatment with anti-CD40 ligand antibodies did not prevent virus-specific humoral responses on second vector challenge. In addition, repeat administration in the murine lung was achieved by using alternate serotypes as well as chemical modification of the capsid of AAV2 to evade existing immunity.
Recent efforts to administer AAV repeatedly to the lung have shifted vector development from AAV2 capsids to novel serotypes, such as AAV9 and those from non-human primates. To assess transduction efficiency of the novel serotype 9, Limberis and Wilson 5 instilled mice intratracheally with AAV2/9 and AAV2/5 vectors expressing the human alpha-1 antitrypsin (hAAT) cDNA and nuclear-targeted LacZ. They observed serum hAAT concentrations in AAV2/9-transduced mice to be roughly 74 times that of AAV2/ 5-transduced animals. AAV2/5 transduced both alveoli and conducting airways, whereas AAV2/9-mediated LacZ expression was seen primarily in alveoli. They reported relatively stable expression for 9 months and noted that AAV2/9 could be re-administered 1 month after initial exposure despite the presence of neutralizing antibodies. 5 Mice previously exposed to AAV2/9 or AAV2/5 expressing hAAT were subjected to a second exposure of the same serotyped vector expressing LacZ. Initial neutralizing antibody titers were higher in serum from animals re-administered with 2/5 than in those treated with AAV2/9. However, after 6 months, neutralizing antibody levels to AAV2/9 exceeded those to AAV2/5. Vector transduction levels in the lung were reported to be roughly 10% lower in animals re-administered with vector than those in naive agematched controls, whereas there was no indication of decreased nasal epithelial transduction. Conversely, transduction was detected in neither lung nor nose in animals given a repeat dose of AAV2/5 serotype vectors. High levels of IgA-and IgG-neutralizing antibodies were detected in bronchoalveolar lavage fluid isolated from these mice in contrast to mice re-administered with AAV2/9. The authors indicated that the antibody response to AAV2/5 vectors was largely systemic. Systemic responses to AAV2/9 were detectable but did not inhibit gene expression. They concluded that AAV2/9 was better able to evade mucosal immunity, 5 presumably by evading interaction with antigenpresenting cells, as serotype-specific differences in activation of CD8T cells to capsid were shown. 12 However, this study did not address the time interval between vector administrations.
A report that investigated the interval between vector administrations was published recently. Sumner-Jones et al. 13 also determined the feasibility of administering AAV5 capsid/AAV5 genome vector (AAV5/5) after initial exposure to the same serotype. They delivered AAV5/5 vectors to the lungs and nasal cavities of mice in either a single dose, or in two or three doses at 8-week intervals. They observed insignificant differences in expression from animals administered three doses compared with those from naive mice. Conversely, animals administered with a single dose of AAV5/5 showed high levels of expression. The decrease in expression from those receiving two and three doses correlated with increased neutralizing antibody titers. When the types of antibody responses were analyzed, the investigators found that the majority of neutralizing antibodies were raised against the AAV5/5 vector, whereas little to no anti-transgene antibodies were detected. In addition, significant repeat transduction was not observed when the interval between administrations was increased to 36 weeks. In contrast to previous reports, delivery of a soluble CTL4-Ig fusion did not enhance repeated transfer. In fact, there was no difference in expression in the lung between naive animals and those re-administered with AAV5/5CTL4Ig. Interestingly, anti-CTL4Ig-neutralizing antibodies were detected in the sera in addition to anti-AAV5 antibodies. Notably, the investigators achieved a successful repeat administration when the initial exposure was to the AAV2 capsid. These data represent the investigation of two delivery routes (intratracheal and intranasal) to one strain of laboratory mouse. The authors note that repeat administration through different routes of delivery and to different model strains might yield alternative results and should be investigated further. 13 In addition to human serotypes, non-human primate AAV serotypes have been explored. AAVrh.10 serotyped vectors achieved high levels of hAAT in the presence of high-level anti-AAV2-and AAV5-neutralizing antibody titers. 13 Titer-matched doses of AAV5-, AAV2-or AAVrh.10-hAAT were injected intrapleurally after Prospects of repeated pulmonary administration PL Sinn et al exposure to AAV5 or AAV2 vector. AAVrh.10 vectors delivered comparable transgene levels in either immunized or naive animals. This was in contrast to AAV2 vectors that failed to achieve detectable serum levels of hAAT when re-administered to immunized mice. Similarly, AAV5 vectors achieved 980-fold lower levels of serum hAAT when re-administered. Interestingly, mice first treated with AAV5-serotyped vector and then re-administered with AAVrh.10 vector showed that serum hAAT levels increased by 300%. The authors conclude that the non-human primate AAVrh10 capsid pseudotype does not elicit an antibody response and could be used to retreat patients with existing immunity to AAV5 or AAV2. In addition, rhesus serotype AAV8 would also be an option, as it achieved the second highest expression levels.
14 Re-administration studies using LVs are beginning to inform the field of their potential for repeated delivery
The LVs are only beginning to make their debut in human clinical trials. 15 Few studies to date have examined the consequences of repeated administration of retroviral-or lentiviral-based vectors in the airways or other tissues.
Using a luciferase reporter and bioluminescence imaging, we showed that pseudotyping a FIV-based LV with the envelope glycoprotein from Autographa californica multicapsid nucleopolyhedrovirus (GP64-FIV) results in persistent in vivo gene expression after the delivery of a single dose to mouse nasal epithelia. Further, we investigated the potential to repeatedly administer GP64-FIV to the respiratory tract and increase gene transfer in mice (Figure 3) . Minimal innate and adaptive immune responses were observed after repeated topical delivery of a LV to murine nasal epithelia. Interestingly, the vector failed to elicit immune responses that prevent re-administration even after seven doses (one dose per week). We showed additive increases in transgene expression (both reporter genes and a therapeutic gene, erythropoietin) with repeat dosing. This increase in expression may represent both an increase in the percentage of cells expressing a transgene and an increase in the number of transgene copies per cell; however, no studies have yet specifically addressed this question.
Buckley et al. 16 recently investigated lentiviral reporter gene expression in mouse lung after a single fetal intraamniotic administration, three administrations (one fetal/two neonatal) and two neonatal administrations. The fetal/neonatal re-administration achieved similar levels of epithelial-cell transduction compared with a single fetal application, but the number of transduced macrophages was increased. Furthermore, neonatal re-administration alone achieved a similar level of macrophage transduction, but reduced levels of epithelial-cell transduction, comparable to levels seen after a single neonatal administration. 16 The authors speculated that this finding represents macrophages infiltrating after the initial dose of GP64-pseudotyped lentivirus, and their subsequent transduction by the second and third doses.
It is possible that some envelopes are more immunogenic than others. However, it is unlikely that preexisting immunity to the insect virus GP64 envelope glycoprotein will present a barrier in humans. We suspect that the GP64 glycoprotein, together with the vector-associated proteins (that is, matrix, capsid, protease, integrase and reverse transcriptase), is poorly antigenic when presented to the nasal mucosa. This phenomenon would presumably be the same in the conducting airways. In addition, the route of vector administration (pulmonary vs systemic delivery) may significantly influence the subsequent development of immune responses. Naldini and co-workers 17 recently reported innate and adaptive immune responses to LVs administered systemically and targeting hepatocytes in mouse models. Our results in the nasal airways suggest that mucosal application of a lentivirus vector is less immunostimulatory than systemic delivery. 2 
Prospects
Advances in immunology will likely inform the field as our understanding of the molecular underpinnings of innate immunity improves. One can envision that pharmacological inhibitors of early innate immune responses might be developed to diminish deleterious responses or blunt adaptive immune responses. Capsid and envelope pseudotyping, directed evolution, and discovery of novel virus capsids or envelopes from other species may continue to provide novel reagents.
To evade the neutralizing antibody response to AAV vectors, several solutions have been proposed-perhaps the most promising of which is modification of the AAV Prospects of repeated pulmonary administration PL Sinn et al capsid. Several groups identified neutralizing epitopes on the AAV2 capsid through peptide scans, ELISA and peptide competition experiments. 6 Information on neutralizing epitopes coupled with work mapping receptor interaction domains resulted in the discovery of capsid modifications, which produce infectious vector that enhance resistance to host neutralizing antibody responses. 6 In addition to rational design, iterative rounds of library generation and selection-known as directed evolution-are effective in producing more infectious vectors in the lung. Recently, Excoffon et al. generated an AAV vector, which was 100-fold more infectious than parental strains, by subjecting the capsid genes from AAV2 and AAV5 to error-prone PCR and DNA shuffling. They subsequently selected the vectors on human airway epithelial cultures. The resulting variant was a chimera between AAV2 amino acids 1-128 and AAV5 amino acids 129-725 with an A581T point mutation. 18 The mutation occurred in a region of AAV5 sialic acid binding, which significantly increased the binding and thus infectivity of the chimera. Furthermore, the newly created chimera carrying the cystic fibrosis transmembrane conductance regulator restored chloride current in cystic fibrosis transmembrane conductance regulatordeficient human airway epithelia to that of wild-type levels. This result is an improvement over gene transfer experiments in the cystic fibrosis transmembrane conductance regulator-deficient cells with AAV2 vector, which were unable to recover chloride current.
Brown et al. 19 recently described a novel strategy to prevent off-target expression of an LV-delivered transgene in antigen-presenting cells. A hematopoietic-specific micro-RNA, miR-142-3p, was incorporated downstream of the transgene, in this case, clotting factor IX. The result was long-lasting transgene expression, no detectable factor IX antibodies and phenotypic correction in a mouse model of hemophilia B. This study exemplifies the use of microRNAs to regulate vector tropism (reviewed in Kelly and Russell 20 ) , and may provide a valuable tool for viral vectors to evade the immune system and allow repeated administration to the lung.
In summary, repeated administration of viral vectors may be necessary for the stable expression of a therapeutic protein over the life of the affected individual, should expression wane over time. Vector re-administration to the respiratory tract offers the possibility to increase the overall transduction efficiency. In addition, sequential vector administration to individual lung lobes may be advantageous for practical and safety reasons. However, before repeated administration of viral vector is feasible in a therapeutic setting, obstacles for each vector system must be addressed. Innate and adaptive immune responses to viral vectors will vary depending on the origin of the vector, the purity of the vector preparation, the envelope or capsid pseudotype, the nucleic acid content, the dose delivered, the route of delivery and the number of administrations. Research in inbred mice has important implications for the translation of gene transfer technology into the development of human pulmonary disease therapies. It will be important in future studies to investigate these approaches in larger, more genetically diverse animal models.
